Project Grant R37CA315065
Award Date 9/3/26
Completion Date 8/31/31
Dollars Obligated $544K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Cleveland, OH 44195, USA
Similar Awards
- The National Institutes of Health National Cancer Institute awarded Cleveland Clinic Lerner College of Medicine of Case Western Reserve University $157,000 on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to identify gut bacterial species that modulate tumor immune checkpoint expression in colorectal cancer using a bioengineered cancer-on-a-chip model. The research investigates how specific bacterial populations influence immune checkpoint molecule expression,...
- The National Cancer Institute awarded Cleveland Clinic Lerner College of Medicine of Case Western Reserve University $640,775 on June 22, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct a co-clinical trial investigating mechanisms by which intratumoral bacteria drive immunosuppression and immune checkpoint inhibitor resistance in head and neck squamous cell carcinoma. The recipient will define how intratumoral bacterial load modulates the immunosuppressive tumor immune...
- The National Cancer Institute awarded Case Western Reserve University $403,686 under the Cancer Biology Research program (CFDA 93.396) on July 1, 2026, to characterize IL-33-responsive mucosal cells in colitis-associated cancer (CAC) pathogenesis. The project grant (R21CA305308) funds exploratory research identifying and functionally determining the precise role of ST2-expressing, IL-33-responsive cells in CAC using two relevant mouse models (AOM/DSS-treated and WINNIE mice). The research...
- The National Cancer Institute awarded the University of California, San Diego $671,226 on May 15, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop engineered native bacteria—host-derived E. coli strains—as a microbial platform for durable, targeted delivery of therapeutic molecules to the gut to prevent or treat colorectal cancer. The research addresses a critical gap in microbial therapies for colorectal cancer, which the American Cancer Society projects will account...
- The National Cancer Institute awarded Fred Hutchinson Cancer Center $727,971 on August 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to characterize the tumor-associated microbiome in early-onset rectal cancers and elucidate the microenvironment of this emerging disease. The award funds a five-year research project (August 1, 2026 through July 31, 2031) examining distinctive microbial features—both bacterial and fungal—in early-onset cancers of the sigmoid colon...
- Federal Grant Award Summary The National Cancer Institute awarded the Regents of the University of Michigan a $2.86 million Project Grant under the Cancer Treatment Research program (CFDA 93.395) to develop and validate a novel microbial-based therapeutic strategy targeting colibactin, a carcinogenic metabolite produced by pathogenic gut bacteria associated with colorectal cancer (CRC). The project, which commenced September 10, 2025, and extends through August 31, 2029, focuses on engineering...
- The National Cancer Institute awarded The Ohio State University $386,888 under CFDA 93.395 (Cancer Treatment Research) on July 2, 2026, to characterize mechanisms by which members of the bacterial family Lachnospiraceae affect response to immune checkpoint blockade (ICB) in cancer treatment. The project builds on prior dietary intervention clinical trials and fecal microbiota transplantation studies showing that microbiome modification can improve ICB response rates. Initial work demonstrated...
- The National Cancer Institute awarded $467,261 to Hackensack University Medical Center on May 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to investigate myeloid phagocyte activation by commensal-activated complement C5AR1 signaling in colorectal cancer. The research examines how tumor-associated microbes—specifically Candida albicans and Fusobacterium nucleatum, two microorganisms enriched in colorectal cancer—amplify C5AR1 signaling to shape the tumor...
- The National Cancer Institute awarded Cold Spring Harbor Laboratory $704,182 under the Cancer Biology Research program (CFDA 93.396) on June 16, 2026, to dissect non-mutational mechanisms driving benign-to-malignant transition in colorectal cancer. The project uses a novel mouse model that stepwise acquires mutations mirroring human colorectal cancer progression—starting with APC knockout to initiate benign polyps, then inducing KRAS G12V and TP53 loss in rare cells within established polyps...
- The National Institutes of Health National Cancer Institute awarded $689,865 to The Trustees of Columbia University in the City of New York on August 5, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop methodological tools and frameworks for cancer microbiome study design and analysis. The award funds development of a comprehensive toolset to address contamination and batch-effect challenges in tumor microbiome research. Specific deliverables include a new method to...